HAIKOU CITY, Hainan, China, Jan. 12 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that China's State Food and Drug Administration ("SFDA") approved the production of Tiopronin Enteric-Coated Capsules. Tiopronin is listed in the National Medical Insurance Program, thus allowing patients to obtain reimbursement.
Tiopronin Tablets are widely prescribed in several countries for the treatment of acute and chronic Hepatitis B (HB), and for the relief of drug-induced liver injury. However, this drug can cause stomach irritation therefore its use and patient compliance may be limited by the side effects. To address this, China Pharma has developed Tiopronin Capsules with an enteric coating to decrease the stomach mucosal irritation associated with Tiopronin. As a result, China Pharma's Tiopronin Enteric-Coated format improves liver function while protecting the stomach.
Ms. Zhilin Li, China Pharma's president and CEO stated: "The competitive
advantage of our enteric coating, coupled with the reimbursement available,
make Tiopronin Enteric-coated Capsules a superior treatment option for liver
disease. According to Chinese epidemiological surveys, there are
approximately 30 million chronic HB patients in China, and around 120 million
carriers of the HB virus, which is 9.95% of the entire population. Therefore,
liver disease is a major threat for the Chinese population. Sales of liver
protection drugs including Tiopronin, have been projected to reach RMB 41.3
billion in 2008*. The increased intestinal absorption of our product,
Tiopronin Enteric-Coated Capsules, is consistent with reduced gastric
irritation, and higher bioavailability. All these advantages of the
enteric-coated format which is the fruit of our product differentiation
strategy, will c
|SOURCE China Pharma Holdings, Inc.|
Copyright©2009 PR Newswire.
All rights reserved